China's independent innovation drug cephalosporine promotes antibiotic research and development and application

the new cephalosporin, known as the "heavy bomb" in antibiotic drugs, has been developed by the Shanghai Pharmaceutical Industry Research Institute and Guangzhou Baiyunshan PharmaceuticalS, changing the long-held view that cephalosporine antibiotics are ineffective against enterocosisIts successful research and development and the promotion and application in the country, has created a huge social and economic benefitsRecently, the research project also won the second prize of the 2006 National Technology Invention, which has become the highest national award for innovative drugs in China in recent yearsCephalosporine is China's first and only independent innovation, with a new structure of semi-synthetic cephalosporin (sein), since 2000 by Guangzhou Baiyunshan Pharmaceutical Co., Ltdexclusive production, has been loaded into the 2005 edition of the People's Republic of China PharmacopoeiaAs a broad-spectrum antibiotic, cephalosporine has a strong antibacterial effect, especially for enterococci, which exceeds all cephalosporine antibiotics used in clinical applicationsClinical studies show that cephalosporine has the characteristics of high blood concentration and good clinical efficacy, and has a total efficiency of 93.61 percent for Gram-positive bacteria (including drug-resistant bacteria)Its application is very wide, respiratory infections, urinary tract infections, skin and soft tissue infections, otolaryngology infections, sepsis, bile duct infections, burns and surgical infections, gynaecological infections, endocarditis and septic meningitis and other infections have a definite efficacy, and high safety, so far there have been no seriousadverse reactionsreportedIn the early 1970s, Professor Wang Wenmei of Shanghai Medical and Technical Institute led the research on cephalospora, which was clinically observed by Professor Dai Ziyingof Shanghai HuashanHospital, and proved that it had good efficacy for Grameen-positive bacteriaHowever, due to the extremely unstable production process of cephalosporine, the finished product is easily discolored at room temperatureIn 1995, Guangzhou Baiyunshan Pharmaceutical Company and Shanghai Medical Institute, after 5 years of efforts to overcome the "bottleneck" in the synthesis process, to achieve industrializationAfter that, they further optimized the process, stabilized and increased the synthetic yield, so that the total synthetic yield increased from 40% to about 60%In addition, they also carried out the product after the market pharmacology and clinical efficacy re-evaluation work, the results again proved that: in today's increasingly serious drug-resistant bacteria, cephalosporine is still sensitive to Gram-positive cocci bacteria, clinical treatment of Gram-positive cocci infection total efficiency of 93.61 percentAt present, it has been recognized by clinical experts as anti-Gram-positive cocci (including drug-resistant strains) infection safe and effective first-line preferred drug, so as to protect the status of the first antibiotic "ace" vancomycin, reducing the opportunity for drug resistance(reproduced from China Medical Daily)